https://alzheimereurope.newsweaver.com/Newsletter/ en-us 03 Mar 2025 04:55:23 CET 03 Mar 2025 04:55:23 CET https://alzheimereurope.newsweaver.com/Newsletter/rss.xml Newsweaver info@alzheimer-europe.org () support@newsweaver.ie (Newsweaver) 60 true https://alzheimereurope.newsweaver.com/Newsletter/xc14cn2flic?lang=en?rss=true Alzheimer Europe's February 2025 newsletter [ https://alzheimereurope.newsweaver.com/Newsletter/1c5dsezwco8/external ] [ https://alzheimereurope.newsweaver.com/Newsletter/1c5dsezwco8/external ] brings you the latest news on developments in the dementia field, across Europe and beyond. Summaries of a few of our top stories appear below. Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond. We are always happy to receive feedback, or suggestions regarding news items to share. [ https://alzheimereurope.newsweaver.com/Newsletter/1c5dsezwco8/external ] 08 Jan 2025 12:00:00 CET 30543f233c374fcc0af2bc2e966c77cb Feature Article <p style="text-align: justify;"><span style="font-size: 12px;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/19/ea8a85fca407401059a769.jpg" style="margin: 5px;" width="133" height="200" hspace="5" vspace="5" alt="Executive Director Jean Georges, June 2024">Alzheimer Europe's <strong><span style="color: rgb(0, 75, 150);"><a href="https://alzheimereurope.newsweaver.com/Newsletter/1c5dsezwco8/external" target="_blank" rel="noreferrer noopener"><strong>February 2025 newsletter</strong></a> </span></strong>brings you the latest news on developments in the dementia field, across Europe and beyond.</span></p> <p style="text-align: justify;"><span style="font-size: 12px;">Summaries of a few of our top stories appear below.</span></p> <p style="text-align: justify;"><span style="font-size: 12px;">Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.</span></p> <p style="text-align: justify;"><span style="font-size: 12px;">We are always happy to receive feedback, or suggestions regarding news items to share.</span></p> <p style="text-align: justify;"> </p> <p class="centered-only" style="text-align: center;"><a href="https://alzheimereurope.newsweaver.com/Newsletter/1c5dsezwco8/external" target="_blank" rel="noreferrer noopener"><img align="middle" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/33/9a2b2c753c2ca4ee114ecc.jpg" style="margin: 0px;" width="200" height="48" hspace="0" vspace="0" alt=""></a></p> https://alzheimereurope.newsweaver.com/Newsletter/lzse2gigkxe?lang=en?rss=true In dementia research, obtaining informed consent presents unique challenges, in part due to participants' cognitive impairments and fluctuating decision-making capacities. Much of the literature on this topic has previously centred on the perspectives of researchers and healthcare professionals, with less focus on individuals with lived experience of dementia. Alzheimer Europe is pleased to have published a perspectives article in the Frontiers in Dementia journal, addressing this gap. 03 Mar 2025 12:00:00 CET adaa2a9d07bceb81b363cab0217f5f1a Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/4a/d872eba120c075e30397ce.jpg" style="margin: 5px;" width="150" height="150" hspace="5" vspace="5" alt="">In dementia research, obtaining informed consent presents unique challenges, in part due to participants' cognitive impairments and fluctuating decision-making capacities. Much of the literature on this topic has previously centred on the perspectives of researchers and healthcare professionals, with less focus on individuals with lived experience of dementia. Alzheimer Europe is pleased to have published a perspectives article in the Frontiers in Dementia journal, addressing this gap.</p> https://www.alzheimer-europe.org/news/alzheimer-europe-perspective-frontiers-dementia-addresses-informed-consent-dementia-research https://alzheimereurope.newsweaver.com/Newsletter/1uvp07i28i6?lang=en?rss=true The Executive Board of the World Health Organization (WHO) has adopted a recommendation to extend the Global Action Plan on the Public Health Response to Dementia 2017-2025, which would see it continue until 2031. The 78th World Health Assembly (WHA), at which the final decision will be made, will be held in May of this year. 03 Mar 2025 12:00:00 CET 4e415944cbf18a95e6a0ada4ef56af16 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/48/a80961dfa2770089c55387.png" style="margin: 5px;" width="150" height="157" hspace="5" vspace="5" alt="">The Executive Board of the World Health Organization (WHO) has adopted a recommendation to extend the Global Action Plan on the Public Health Response to Dementia 2017-2025, which would see it continue until 2031. The 78<sup>th</sup> World Health Assembly (WHA), at which the final decision will be made, will be held in May of this year.</p> https://www.alzheimer-europe.org/news/world-health-organization-executive-board-adopts-recommendation-global-dementia-plan-extension https://alzheimereurope.newsweaver.com/Newsletter/9u0ipfmynv7?lang=en?rss=true It is with great pleasure that we introduce the 47th edition of our Dementia in Europe magazine. Following the 34th Alzheimer Europe Conference (34AEC) in Geneva, (Switzerland), it has been a busy period with lots of interesting developments across Europe in relation to policy, research, culture, advocacy and dementia care. Be sure to check out our special supplement to this magazine, also, focusing on our Annual Conference in Geneva. 03 Mar 2025 12:00:00 CET 9f15041cf2657c898eeeb40fa727e9b3 Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/d2/ef8ea9f2c0e8bf890f2f3a.jpg" style="margin: 5px;" width="150" height="150" hspace="5" vspace="5" alt="">It is with great pleasure that we introduce the 47th edition of our Dementia in Europe magazine. Following the 34th Alzheimer Europe Conference (34AEC) in Geneva, (Switzerland), it has been a busy period with lots of interesting developments across Europe in relation to policy, research, culture, advocacy and dementia care. Be sure to check out our special supplement to this magazine, also, focusing on our Annual Conference in Geneva.</p> https://www.alzheimer-europe.org/news/alzheimer-europe-presents-47th-edition-dementia-europe-magazine https://alzheimereurope.newsweaver.com/Newsletter/168seoaj4xe?lang=en?rss=true The European Medicines Agency (EMA) has reaffirmed its positive opinion on lecanemab, after discussions at the February Committee for Medicinal Products for Human Use (CHMP) meeting. The European Commission had asked the CHMP to consider updating its opinion, following new information on the safety of lecanemab, but after the February CHMP meeting the EMA announced that no updates would be required to its opinion. 03 Mar 2025 12:00:00 CET 43ab84c654a11c40acf14dc752824e8e Other Articles <p style="text-align: justify;"><img align="left" src="http://alzheimereurope.newsweaver.com/v3files/shard1/56305/00/234776c6d3e8b80254761d.jpg" style="margin: 5px;" width="150" height="150" hspace="5" vspace="5" alt="">The European Medicines Agency (EMA) has reaffirmed its positive opinion on lecanemab, after discussions at the February Committee for Medicinal Products for Human Use (CHMP) meeting. The European Commission had asked the CHMP to consider updating its opinion, following new information on the safety of lecanemab, but after the February CHMP meeting the EMA announced that no updates would be required to its opinion.</p> https://www.alzheimer-europe.org/news/european-medicines-agency-reaffirms-positive-opinion-lecanemab-european-commission